Related Experiment Video
Updated: Aug 11, 2025

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
Published on: July 3, 2014
Risk and Management of Patients with Cancer and Heart Disease
Loreena Hill1,2, Bruno Delgado3,4, Ekaterini Lambrinou5
1School of Nursing and Midwifery, Queen's University, 97 Lisburn Road, Belfast, BT9 7BL, UK. l.hill@qub.ac.uk.
Abstract:
Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient's myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients' functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.
More Related Videos
Related Concept Videos
Pericarditis IV: Nursing Management
Cardiomyopathy VI: Nursing Management
Rheumatic Heart Disease IV: Nursing Management
Angina IV: Management
Mitral Regurgitation IV: Nursing Management
Heart Failure VII: Nursing Interventions

